EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Longitudinal Relationship Between Elevated Liver Biochemical Tests and Negative Clinical Outcomes in Primary Biliary Cholangitis: A Population‐Based Study

Kris V Kowdley, David W Victor, Joanna P MacEwan, Radhika Nair, Alina Levine, Jennifer Hernandez, Leona Bessonova, Jing Li, Darren Wheeler, Gideon Hirschfield iD

Alimentary Pharmacology & Therapeutics · 2025-06 · 61 (11) · 1775-1784

DOI: 10.1111/apt.70120 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alimentary Pharmacology & Therapeutics, online erschienen am 02.04.2025. Verfasst von Kris V Kowdley und 9 weiteren Autor:innen. Beteiligte Einrichtung: Liver Institute Northwest and Elson S. Floyd College of Medicine, Washington State University, Seattle, Washington, USA. Hauptthemen laut MEDLINE: Liver Cirrhosis, Biliary, Alkaline Phosphatase. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Intercept Pharmaceuticals.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Elevated liver biochemistries are associated with increased risk of negative outcomes in patients with primary biliary cholangitis (PBC).

Aims

To evaluate whether longitudinal monitoring of liver biochemistries and fibrosis scores provides additional prognostic value and to assess the relationship between the degree of elevation of multiple biomarkers within different alkaline phosphatase (ALP) strata.

Methods

Adults with PBC were identified from Komodo's Healthcare Map. A Cox proportional hazards model examined time to first occurrence of hospitalisation due to hepatic decompensation, liver transplantation, or death as a function of the proportion of time during follow‐up that liver biochemistries and fibrosis scores exceeded thresholds. Within ALP strata (ALP ≤ upper limit of normal [ULN]; ALP>ULN to ≤ 1.67 × ULN; ALP > 1.67 × ULN), separate multivariate Cox hazard models assessed the association between time‐varying covariates and the composite endpoint.

Results

Overall, 3974 patients were included; 88.2% were female, with a mean age of 59.4 years. The median follow‐up was 2.5 years. Increasing magnitude and duration beyond established thresholds of ALP, alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TB), AST/platelet ratio index (APRI) and fibrosis‐4 (FIB‐4) were associated with increased risk of negative outcomes. Elevated ALT, AST, TB, APRI and FIB‐4 were associated with increased risk of negative outcomes across all ALP strata.

Conclusions

Prolonged elevation of multiple hepatic biomarkers and fibrosis scores is associated with a greater risk of negative clinical outcomes, underscoring the importance of ongoing monitoring beyond the guideline‐recommended initial treatment response to guide timely treatment decisions and improve PBC management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver Cirrhosis, BiliaryAlkaline PhosphataseHumansFemaleMaleMiddle AgedBiomarkersAgedLongitudinal StudiesLiver Function TestsProportional Hazards ModelsAspartate AminotransferasesPrognosisAlanine TransaminaseAdult

Stichwörter der Autor:innen

clinical outcomeshepatic failureliver function testprimary biliary cholangitisrisk factor

Substanzen

BiomarkersAlkaline PhosphataseAspartate AminotransferasesAlanine Transaminase

Autor:innen und Institutionen

  • Liver Institute Northwest and Elson S. Floyd College of Medicine, Washington State University, Seattle, Washington, USA.
  • Houston Methodist Hospital, Houston, Texas, USA.
  • Genesis Research Group, Hoboken, New Jersey, USA.
  • Intercept Pharmaceuticals, Morristown, New Jersey, USA.
  • The Autoimmune and Rare Liver Disease Programme, Division of Gastroenterology and Hepatology, Toronto General Hospital, Toronto, Ontario, Canada.

ORCID-Profile: Gideon Hirschfield

Förderung

  • Intercept Pharmaceuticals

Zitieren

APA

Kowdley, K. V., Victor, D. W., MacEwan, J. P., Nair, R., Levine, A., Hernandez, J., Bessonova, L., Li, J., Wheeler, D., & Hirschfield, G. (2025). Longitudinal Relationship Between Elevated Liver Biochemical Tests and Negative Clinical Outcomes in Primary Biliary Cholangitis: A Population‐Based Study. Alimentary Pharmacology & Therapeutics, 61(11), 1775-1784. https://doi.org/10.1111/apt.70120

Vancouver

Kowdley KV, Victor DW, MacEwan JP, Nair R, Levine A, Hernandez J, et al. Longitudinal Relationship Between Elevated Liver Biochemical Tests and Negative Clinical Outcomes in Primary Biliary Cholangitis: A Population‐Based Study. Alimentary Pharmacology & Therapeutics. 2025;61(11):1775-1784. doi:10.1111/apt.70120

BibTeX
@article{Kowdley2025,
  author = {Kowdley, Kris V and Victor, David W and MacEwan, Joanna P and Nair, Radhika and Levine, Alina and Hernandez, Jennifer and Bessonova, Leona and Li, Jing and Wheeler, Darren and Hirschfield, Gideon},
  title = {Longitudinal Relationship Between Elevated Liver Biochemical Tests and Negative Clinical Outcomes in Primary Biliary Cholangitis: A Population‐Based Study},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2025},
  volume = {61},
  number = {11},
  pages = {1775--1784},
  doi = {10.1111/apt.70120}
}
Kostenlos starten →